Nature of the Event
Jagsonpal Pharmaceuticals Limited has entered into a definitive agreement to acquire 85% equity stake in Aequitas Healthcare Private Limited, a Mumbai-based pharmaceutical company focused on sale and distribution of pharmaceutical products to hospitals. This marks Jagsonpal's strategic entry into the hospital segment.
Key Quantitative Figures
- Acquisition of 85% equity stake in Aequitas Healthcare Private Limited
- Total consideration: ₹20.8 crores
- Aequitas Healthcare revenue in FY26: ₹53 crores
- Funding source: Internal accruals of Jagsonpal
- Current Aequitas directors will retain 15% stake
Parties Involved
- Acquiring company: Jagsonpal Pharmaceuticals Limited (Scrip Code: 507789, NSE Symbol: JAGSNPHARM)
- Target company: Aequitas Healthcare Private Limited
- Legal advisors: J Sagar & Associates (for Jagsonpal), Noverra Partners (for Aequitas)
- Key personnel: Manish Gupta (Managing Director, Jagsonpal), Amrut Medhekar (Chief Operating Officer, Jagsonpal), Shailesh Kamat (Director and largest shareholder, Aequitas)
Purpose and Strategic Rationale
Strategic entry into hospital segment, which contributes approximately 10% of pharma industry sales and is growing faster. Provides ready platform for meaningful presence in hospital segment. Expected to benefit Jagsonpal's portfolio of established brands through Aequitas' strong institutional relationships.
Company Background
Aequitas Healthcare was founded in 2017 and has robust business covering all leading hospital chains in India. Jagsonpal Pharmaceuticals has over five decades of experience in Indian pharmaceutical market with portfolio focusing on Gynaecology, Orthopaedics, and Dermatology segments. Company has 20+ brands among Top 5 brands in their molecule category and sales team of over 1000 professionals.
Transaction Details
- Transaction subject to fulfilment of customary closing conditions
- Current directors of Aequitas shall continue to be associated with the business
- Represents structural pivot from legacy retail prescription player to Omnichannel Specialty healthcare business